Clinical trial · Observational
Involvement of SK3 Calcium Channel in Taxane Neuropathy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Taxane neuropathy is a common and long-term side effect of long-term morbidity in patients surviving cancer. No preventive or symptomatic treatment has been shown to be effective. Its pathophysiology is poorly known and probably multifactorial. A possible mechanism would be mediated by the activation of the SK3 calcium channel: a retrospective study carried out at the University Hospital of Tours (Carina RUA) found a significant association between the number of CAG triplets in the KCNN3 gene coding for the SK3 channel and the appearance of a taxane neuropathy.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Chemotherapy-induced Peripheral Neuropathy | — | UNRESOLVED | — |
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood samples | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Breast or prostate cancer
- description
- Taken blood samples on patients hospitalized in medical oncology day hospital at the University Hospital of Tours or CHC oncology day hospital, for their chemotherapy with taxanes (paclitaxel or docetaxel) for breast or prostate cancer
- interventionNames
- Other: Blood samples
Primary outcomes (2)
- measure
- Appearance of a neuropathy secondary to taxanes using Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE)
- timeFrame
- From baseline and up to 4 months of follow-up
- description
- Evaluation of neuropathy will be performed using non-invasive test, gold standard, Cancer Institute Common Terminology Criteria for Adverse Events Grading (from best to worst) : 0 = normal 1. = slight paresthesia, mild weakness (subjective) 2. = moderate paresthesia, moderate weakness (objective) 3. = severe paresthesia with functional disability, severe weakness 4. = paralysis
- measure
- Appearance of a neuropathy secondary to taxanes using Total neuropathy score clinical (TNSc)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Breast Group * Age ≥ 18 years * Breast cancer * Chemotherapy with paclitaxel or docetaxel * Adjuvant or neoadjuvant chemotherapy in localized cancer or first-line treatment in metastatic cancer * Signed informed consent Prostate Group * Age ≥ 18 years * Metastatic prostate cancer * Chemotherapy with docetaxel in 1st line * Signed informed consent Exclusion Criteria: * Anteriority or concomitance of another chemotherapy provider of neuropathy (platinum salts) * Another possible cause of neuropathy: diabetes, alcoholism, vitamin B9 / B12 deficiency, neurodegenerative disease, Raynaud's syndrome
References
Publications (0)
Data not yet available